Cost–utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan

Current Medical Research and Opinion

Volumn 33, Issue 1, 2017, Pages 11-21

  Igarashi, Ataru ^a   Tang, Wentao ^a   Guerra, Ines ^b   Marié, Lucile ^b   Cure, Sandrine ^b   Lopresti, Michael ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b Mapi   (United Kingdom)

^c Junicon Japan Inc   (Japan)

Author keywords

Chronic hepatitis C infection; Cost utility analysis; Daclatasvir; Japan; Ledipasvir sofosbuvir; Simeprevir; Telaprevir

Indexed keywords

ASUNAPREVIR; DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; JAPAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MARKOV CHAIN; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; SOFOSBUVIR;

EID: 84986213401     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1222513     Document Type: Article

References (42)

1. Shepherd J, Jones J, Hartwell D, et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C:a systematic review and economic evaluation. Health Technol Assess 2007;11:1-224
2. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(Suppl 2):30-60
3. Chen SL, Morgan TR., The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
4. Guidelines for the management of hepatitis C virus infection:first edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013;43:1-34
5. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International 2011;31:61-80
6. Kanda T, Imazeki F, Azemoto R, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011;56:3335-42
7. Lawitz E, Gane E, Stedman C, et al. GS-7977 phase II trials:concordance of SVR4 with SVR12 and SVR24 in HCV genotypes 1-3. Presentation, EASL 18–22 April 2012, Barcelona. Available at:https://www.nice.org.uk/guidance/ta252
8. Poynard T, Marcellin P, Bissery A, et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon:a randomized trial. J Viral Hepatitis 2003;10:197-204
9. [JSH Guidelines for the Management of Hepatitis C Virus Infection]. 2015. Available at:https://www.jsh.or.jp/files/uploads/HCV_GL_ver4_Sept01_final.pdf [Last accessed16 September 2015]
10. Tanaka A., [JSH guidelines for the management of hepatitis C virus infection (version 3)]. Nihon Rinsho Japan J Clin Med 2015;73:221-7
11. Drenth JP., HCV treatment–no more room for interferonologists? N Engl J Med 2013;368:1931-2
12. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88
13. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
14. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
15. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C:an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-53
16. Hartwell D, Jones J, Baxter L, Shepherd J., Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection:a systematic review and economic evaluation. Health Technol Assess 2011;15:i-210
17. Cure S, Guerra I, Dusheiko G., Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat 2015;22:882-9
18. Fukuda TST, Ikeda S, Igarashi A, et al. [Guideline for economic evaluation of healthcare technologies in Japan]. J Natk Inst Public Health 2013;62:625-40
19. Telavic PMS interim report. 2014. Available at:http://medical.mt-pharma.co.jp/intro/tlv/investigation/pdf/tlv-zenrei201409.pdf [Last accessed 16 September 2015]
20. Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection:the CONCERTO-4 study. Hepatol Res 2015;45:501-13
21. JSH guidelines for the management of hepatitis C virus infection:a 2014 update for genotype 1. Hepatol Res 2014;44(Suppl S1):59-70
22. Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012;19:e134-42.w20
23. Nakamura J, Terajima K, Aoyagi Y, Akazawa K., Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Experimental Med 2008;215:33-42
24. Ishida H, Yotsuyanagi H. [Study of the cost-effectiveness of the standard treatment for chronic hepatitis C]. Ministry of Health Labour and Welfare grants system. Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do? resrchNum=201333004B [Last accessed 16 September 2015]
25. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma:incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7
26. Statistics Bureau of the Ministry of Internal Affairs and Communication. Table 2-35 Complete Life Table (1891N2000) 25/06/2015. Statistics Bureau of the Ministry of Internal Affairs and Communication. Avilable at:http://www.stat.go.jp/data/chouki/02.htm [Last accessed 25/ 06/2015]
27. Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C:evidence from a national survey in Japan. Value Health 2012;15(1 Suppl):S65-S71
28. Sugimori H., [Study of utility for hepatitis]. Ministry of Health Labour and Welfare grants system. Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B [Last accessed 16 September 2015]
29. Gilead Sciences. Health State Utilities for HCV (SF6D). 2014
30. National Institute for Health and Care Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C–NICE technology appraisal guidance 252. 2012. Available at:guidance.nice.org.uk/ta252 [Last accessed 18 June 2012]
31. Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C:randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
32. 2015 National Drug Tariff. Ministry of Health, Labour and Welfare. Available at:http://www.mhlw.go.jp/topics/2014/03/tp0305-01.html [Last accessed 15 September 2015]., 2015
33. Ikeda T., [Medical expenses for the viral liver diseases]. Ministry of Health Labour and Welfare grants system. Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B [Last accessed 16 September 2015]
34. Ishida H., [Study of the cost-effectiveness of the standard treatment for chronic hepatitis C]. Ministry of Health Labour and Welfare grants system. Available at:https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201333004B [Last accessed 16 September 2015]
35. Briggs A, Sculpher M, Claxton K., Decision modelling for health economic evaluation. 2006, Oxford University Press.
36. Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained:what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
37. Shiroiwa T, Igarashi A, Fukuda T, Ikeda S., WTP for a QALY and health states:more money for severer health states? Cost Effectiveness Resource Allocation 2013;11:22
38. Chhatwal J, Kanwal F, Roberts MS, Dunn MA., Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397-406
39. Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544-63
40. Curry MP, Bacon B, Dieterich D, et al. Effectiveness of 8 or 12 week LDV-SOF in treatment-naïve patients with non-cirrhotic, genotype 1 hepatitis C:real-world experience from the TRIO Network. Paper presented at:66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015, Boston, MA, USA
41. Curry MP, Bacon B, Dieterich D, et al. Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 hepatitis C:real-world experience from the TRIO Network. Paper presented at:66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015, Boston, MA, USA
42. Terrault N, Zeuzem S, Di, Bisceglie AM, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection:analysis of a multicenter prospective, observational study. Paper presented at:66th Annual Meeting of the American Association for the Study of Liver Diseases, 2015, Boston, MA, USA